361 related articles for article (PubMed ID: 25380949)
1. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
3. Living Donor Preemptive Kidney Transplantation in Tuberous Sclerosis Complex Patient and the Role of Mammalian Target of Rapamycin Inhibitor: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E
Transplant Proc; 2020 Oct; 52(8):2520-2523. PubMed ID: 32448667
[TBL] [Abstract][Full Text] [Related]
4. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
5. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
[TBL] [Abstract][Full Text] [Related]
7. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
[TBL] [Abstract][Full Text] [Related]
8. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
10. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
11. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
Lechuga L; Franz DN
Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
[No Abstract] [Full Text] [Related]
12. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
13. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
[TBL] [Abstract][Full Text] [Related]
16. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero R; Coniglio A; Garaci F; Curatolo P
Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
[TBL] [Abstract][Full Text] [Related]
17. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
[TBL] [Abstract][Full Text] [Related]
18. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
19. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
[TBL] [Abstract][Full Text] [Related]
20. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]